Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
|
2 min read
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.
|
2 min read